ArticleProceedings of the National Academy of Sciences of the United States of America1996
Pax3 modulates expression of the c-Met receptor during limb muscle development.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 360 citations in OpenAlex.
- PAX3: A Driver of Normal Development and Disease.Biomolecules · 2026Review
- Article
- The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.Cell reports. Medicine · 2025Review
- SIX1+PAX3+ identify a progenitor for myogenic lineage commitment from hPSCs.Development (Cambridge, England) · 2023Article
- Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma.Cancers · 2023Review
- Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.Scientific reports · 2022Article
- PAX Genes in Cardiovascular Development.International journal of molecular sciences · 2022Review
- Are Copy Number Variations within theAnimals : an open access journal from MDPI · 2022Article
- MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression.Frontiers in oncology · 2022Article
- Tripeptide Leu-Pro-Phe from Corn Protein Hydrolysates Attenuates Hyperglycemia-Induced Neural Tube Defect in Chicken Embryos.Oxidative medicine and cellular longevity · 2022Article
- Master regulators of skeletal muscle lineage development and pluripotent stem cells differentiation.Cell regeneration (London, England) · 2021Review
- M-Cadherin Is a PAX3 Target During Myotome Patterning.Frontiers in cell and developmental biology · 2021Article
- Cellular dynamics of myogenic cell migration: molecular mechanisms and implications for skeletal muscle cell therapies.EMBO molecular medicine · 2020Review
- Mechanisms of Congenital Malformations in Pregnancies with Pre-existing Diabetes.Current diabetes reports · 2020Review
- Five transcriptional factors reprogram fibroblast into myogenic lineage cells via paraxial mesoderm stage.Cell cycle (Georgetown, Tex.) · 2020Article
- Article
- Pax3 cooperates with Ldb1 to direct local chromosome architecture during myogenic lineage specification.Nature communications · 2019Article
- The zebrafish HGF receptor met controls migration of myogenic progenitor cells in appendicular development.PloS one · 2019Article
- Review
- In Vitro Tissue-Engineered Skeletal Muscle Models for Studying Muscle Physiology and Disease.Advanced healthcare materials · 2018Review
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Pax3 is a transcription factor whose expression has been used as a marker of myogenic precursor cells arising in the lateral somite destined to migrate to and populate the limb musculature. Accruing evidence indicates that the embryologic origins of axial and appendicular muscles are distinct, and limb muscle abnormalities in both mice and humans harboring Pax3 mutations support this distinction. The mechanisms by which Pax3 affects limb muscle development are unknown. The tyrosine kinase receptor for hepatocyte growth factor/scatter factor encoded by the c-met protooncogene is also expressed in limb muscle progenitors and, like Pax-3, is required in the mouse for limb muscle development. Here, we show that c-met expression is markedly reduced in the lateral dermomyotome of Splotch embryos lacking Pax3. We show that Pax3 can stimulate c-met expression in cultured cells, and we identify a potential Pax3 binding site in the human c-MET promoter that may contribute to direct transcriptional regulation. In addition, we have found that several cell lines derived from patients with rhabdomyosarcomas caused by a t(2;13) chromosomal translocation activating PAX3 express c-MET, whereas those rhabdomyosarcoma cell lines examined without the translocation do not. These results are consistent with a model in which Pax3 modulates c-met expression in the lateral dermomyotome, a function that is required for the appropriate migration of these myogenic precursors to the limb where the ligand for c-met (hepatocyte growth factor/scatter factor) is expressed at high levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.